Onconetix, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Onconetix, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $815.4K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.52M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $58.5K | Jun 2, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $632.9K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.06M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($1.13M) | Jun 2, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.03M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($58.69M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($37.41M) | Jun 2, 2025 |
| FY2022 | Dec 31, 2022 | ($13.42M) | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | ($3.42M) | Mar 9, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.86M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($56.49M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($36.03M) | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | ($13.48M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($3.42M) | Mar 9, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $154.4K | Jun 2, 2025 |
| FY2024 | Dec 31, 2023 | $1.95M | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | $4.13M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.33M | Mar 9, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.04M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $11.23M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $14.77M | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | $9.35M | Apr 11, 2024 |
| FY2023 | Oct 31, 2022 | $254.0K | Apr 11, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.68M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($10.50M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($13.58M) | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | ($8.68M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($2.04M) | Mar 9, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $28.5K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $3.3K | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | $9.3K | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.9K | Mar 9, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.93M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $28.18M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $87.52M | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | $26.31M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $3.08M | Mar 9, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.16M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $18.57M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $21.88M | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | $3.92M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.64M | Mar 9, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.54M | Jun 2, 2025 |
| FY2024 | Dec 31, 2023 | ($5.60M) | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | $22.39M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.45M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $4.73M | Mar 9, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.55M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $27.05M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $55.68M | Mar 13, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($131.21M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($115.68M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($56.79M) | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | ($19.38M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($5.96M) | Mar 9, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $25.75M | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | $1.93M | Mar 9, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (1,823) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (87) | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (1,823) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (87) | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.56M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 138,270 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 558,099 | Jun 2, 2025 |
| FY2023 | Dec 31, 2022 | 15.27M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | 3.20M | Mar 9, 2023 |